top of page

Switching to Faricimab may maintain BCVA and increase durability

A study in Japan indicates that switching to Faricimab (Vabysmo, Genentech) treatment using a treat-and-extend (TAE) regimen appears to maintain the best-corrected visual acuity (BCVA) and extend the injection interval in patients with neovascular age-related macular degeneration (nAMD), resulting in enhanced satisfaction 6 months after patients were switched. This was reported by Dr. Taiichi Hikichi, who is in private practice in Sapporo, Japan, in the Japanese Journal of Ophthalmology.

Dr Hikichi conducted a retrospective observational study of 48 consecutive eyes of 48 patients with nAMD who were switched to faricimab and followed for 6 months while they were on a TAE regimen. At the 6-month time point, the patients completed the Macular Disease Treatment Satisfaction Questionnaire (MacTSQ).

The results showed that the BCVA was maintained 6 months after the patients were switched to the faricimab TAE regimen. In addition, the mean central foveal thickness decreased significantly (p < 0.001) at 6 months compared to the time at which patients started on faricimab from 372 ± 20 μm to 272 ± 14 μm.

The treatment interval following the switch was 10.45 ± 0.44 weeks, which differed significantly (p = 0.002) from the treatment interval of 6.72 ± 0.34 weeks at the time of the switch.

Dr Hikichi also reported that the MacTSQ total score of 58.8 ± 1.7 in eyes with a BCVA of 20/40 and better 6 months after the switch was significantly (p < 0.001). higher compared to that in eyes with a BCVA worse than 20/40 (48.2 ± 1.5). The MacTSQ total score of 56.8 ± 1.8 in eyes in which a 4-week extension of the injection interval was achieved was significantly higher than the 49.5 ± 1.9 in eyes without (p < 0.001).

Dr. Hikichi concluded that switching to faricimab administered using a TAE regimen seems to maintain the BCVA and extend the injection interval in patients with nAMD, resulting in enhanced patient satisfaction.

To read the academic paper, click here.

14 views0 comments


bottom of page